Literature DB >> 31025149

Inhibitory effect of carbonyl reductase 1 against peritoneal progression of ovarian cancer: evaluation by ex vivo 3D-human peritoneal model.

Hiroe Oikiri1, Yoshiya Asano2, Michiya Matsusaki3, Mitsuru Akashi4, Hiroshi Shimoda2,5, Yoshihito Yokoyama6.   

Abstract

The current authors previously reported that a carbonyl reductase 1 (CR1) DNA-dendrimer complex could potentially be used in gene therapy for peritoneal metastasis of ovarian cancer. The aims of the current study were to observe the cellular dynamics of peritoneal metastasis of epithelial ovarian cancer cells and to ascertain changes in the dynamics of ovarian cancer cells as a result of transfection of CR1 DNA. (1) Artificial human peritoneal tissue (AHPT) was seeded with serous ovarian cancer cells, and the process leading to development of peritoneal carcinomatosis was observed over time. (2) Peritoneal carcinomatosis was produced in mice and compared to a model using AHPT to determine the appropriateness of AHPT. (3) CR1 DNA was transfected into cancer cells seeded on AHPT, and the dynamics of cancer cells were observed over time. (1) Cancer cells perforated the mesothelium, leaving normal mesothelium intact. However, the cells proliferated between the layers of the mesothelium, forming a mass. After 24 h, cancer cells had invaded the lymphatics, and after 48-72 h cancer cells had invaded deep into the mesothelium, where they formed a mass. (2) Invasion of the peritoneum by cancer cells in a murine model of peritoneal carcinomatosis resembled that in a model using AHPT, and results substantiated the reproducibility of peritoneal carcinomatosis in AHPT. (3) Proliferation of cells transfected with CR1 DNA was significantly inhibited on AHPT, and necrosis was evident. Nevertheless, cancer cell invasion deep into the mesothelium was not inhibited. Use of a new tool, AHPT, in an in vitro model of peritoneal metastasis revealed that CR1 DNA inhibited cancer cell proliferation. CR1 DNA does not play a role in inhibiting invasion of the mesothelium during peritoneal metastasis, but it does affect cancer cell proliferation. Results suggested that CR1 DNA inhibits cancer cell proliferation via necrosis.

Entities:  

Keywords:  Artificial human peritoneal tissue; Carbonyl reductase 1; Necrosis; Ovarian cancer; Peritoneal metastasis

Mesh:

Substances:

Year:  2019        PMID: 31025149     DOI: 10.1007/s11033-019-04788-6

Source DB:  PubMed          Journal:  Mol Biol Rep        ISSN: 0301-4851            Impact factor:   2.316


  25 in total

1.  Carcinoma of the ovary. FIGO 26th Annual Report on the Results of Treatment in Gynecological Cancer.

Authors:  A P M Heintz; F Odicino; P Maisonneuve; M A Quinn; J L Benedet; W T Creasman; H Y S Ngan; S Pecorelli; U Beller
Journal:  Int J Gynaecol Obstet       Date:  2006-11       Impact factor: 3.561

2.  Redistribution of resistance and sensitivity to platinum during the observation period following treatment of epithelial ovarian cancer.

Authors:  Yoshihito Yokoyama; Masayuki Futagami; Jun Watanabe; Naoki Sato; Yukihiro Terada; Fumiharu Miura; Toru Sugiyama; Tadao Takano; Nobuo Yaegashi; Takanobu Kojimahara; Hirohisa Kurachi; Hiroshi Nishiyama; Keiya Fujimori; Toru Tase; Hideki Mizunuma
Journal:  Mol Clin Oncol       Date:  2013-12-10

3.  Clofibric acid, a peroxisome proliferator-activated receptor alpha ligand, inhibits growth of human ovarian cancer.

Authors:  Yoshihito Yokoyama; Bing Xin; Tatsuhiko Shigeto; Mika Umemoto; Akiko Kasai-Sakamoto; Masayuki Futagami; Shigeki Tsuchida; Fahd Al-Mulla; Hideki Mizunuma
Journal:  Mol Cancer Ther       Date:  2007-04       Impact factor: 6.261

4.  Decreased expression of carbonyl reductase 1 promotes ovarian cancer growth and proliferation.

Authors:  Yuki Osawa; Yoshihito Yokoyama; Tatsuhiko Shigeto; Masayuki Futagami; Hideki Mizunuma
Journal:  Int J Oncol       Date:  2014-12-30       Impact factor: 5.650

5.  Cancer statistics, 2013.

Authors:  Rebecca Siegel; Deepa Naishadham; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2013-01-17       Impact factor: 508.702

6.  Evaluation of new platinum-based treatment regimens in advanced-stage ovarian cancer: a Phase III Trial of the Gynecologic Cancer Intergroup.

Authors:  Michael A Bookman; Mark F Brady; William P McGuire; Peter G Harper; David S Alberts; Michael Friedlander; Nicoletta Colombo; Jeffrey M Fowler; Peter A Argenta; Koen De Geest; David G Mutch; Robert A Burger; Ann Marie Swart; Edward L Trimble; Chrisann Accario-Winslow; Lawrence M Roth
Journal:  J Clin Oncol       Date:  2009-02-17       Impact factor: 44.544

7.  Human carbonyl reductase. Nucleotide sequence analysis of a cDNA and amino acid sequence of the encoded protein.

Authors:  B Wermuth; K M Bohren; G Heinemann; J P von Wartburg; K H Gabbay
Journal:  J Biol Chem       Date:  1988-11-05       Impact factor: 5.157

8.  A functional genetic polymorphism on human carbonyl reductase 1 (CBR1 V88I) impacts on catalytic activity and NADPH binding affinity.

Authors:  Vanessa Gonzalez-Covarrubias; Debashis Ghosh; Sukhwinder S Lakhman; Lakshmi Pendyala; Javier G Blanco
Journal:  Drug Metab Dispos       Date:  2007-03-07       Impact factor: 3.922

9.  Inhibitory effect of carbonyl reductase 1 on ovarian cancer growth via tumor necrosis factor receptor signaling.

Authors:  Rie Miura; Yoshihito Yokoyama; Tatsuhiko Shigeto; Masayuki Futagami; Hideki Mizunuma
Journal:  Int J Oncol       Date:  2015-10-13       Impact factor: 5.650

10.  Carbonyl reductase as a significant predictor of survival and lymph node metastasis in epithelial ovarian cancer.

Authors:  M Umemoto; Y Yokoyama; S Sato; S Tsuchida; F Al-Mulla; Y Saito
Journal:  Br J Cancer       Date:  2001-09-28       Impact factor: 7.640

View more
  1 in total

1.  A human ex vivo coculture model to investigate peritoneal metastasis and innovative treatment options.

Authors:  Dina Mönch; Jana Koch; Annika Maaß; Nicole Janssen; Thomas Mürdter; Philipp Renner; Petra Fallier-Becker; Wiebke Solaß; Matthias Schwab; Marc-H Dahlke; Hans J Schlitt; Tobias Leibold
Journal:  Pleura Peritoneum       Date:  2021-07-27
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.